Ines Thiele

1 week ago | sciencedirect.com | Giovanni Rigoni |Maria Soriano |Almut Heinken |Ines Thiele

In recent years, the treatment of inflammatory bowel disease (IBD) has undergone revolutionary changes with the emergence of therapies that block the action of inflammatory cytokines, represented by infliximab and ustekinumab (UST).1 UST was approved for the treatment of Crohn’s disease (CD) in the United States and the European Union in 2016, and in China in 2020.2 Up to now, a substantial amount of prospective and retrospective studies around the world have confirmed the effectiveness of...

Nov 12, 2024 | nature.com | Ines Thiele

Correction to: Scientific Reports https://doi.org/10.1038/s41598-024-55960-3, published online 13 March 2024. The original version of this Article contained an error in the Abstract. “Notably, AD individuals displayed diminished formate microbial secretion in these models.” now reads:“We predicted microbial formate as well as other microbial metabolites, which could alter urine formate production in the host-microbiome personalised models.” The original Article has been corrected.

Jul 26, 2023 | nature.com | Pirro G. Hysi |Annemarie I. Luik |Karl-Heinz Ladwig |Cristina Menni |M. Arfan Ikram |Karsten Suhre | +8 more

AbstractMetabolome reflects the interplay of genome and exposome at molecular level and thus can provide deep insights into the pathogenesis of a complex disease like major depression.